Cocaine and amphetamine use in patients with psychiatric: Illness a randomized trial of typical antipsychotic continuation or discontinuation

E. Sherwood Brown, Vicki A. Nejtek, Dana C. Perantie, Nancy Rajan Thomas, A. John Rush

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Animal studies indicate that typical antipsychotics (neuroleptics) increase cocaine and amphetamine self-administration. Patients with psychiatric illnesses have high rates of substance abuse and frequently receive chronic typical antipsychotic therapy. This open, pilot study examined the effect of typical antipsychotic discontinuation on cocaine and amphetamine use in patients with psychiatric illnesses. Twenty-four evaluable outpatients were randomized to continue (n = 12) or discontinue (n = 12) chronic typical antipsychotic therapy. The atypical antipsychotic quetiapine was instituted, when necessary, for psychosis in the discontinuation group (n = 8). Participants were assessed weekly over 12 weeks with measures of psychiatric symptoms, drug use, and drug craving. Those discontinuing typical antipsychotics (n = 12) had significant reductions in drug craving compared with those continuing typical antipsychotics. No significant between-group differences in drug use were found. Typical antipsychotic discontinuation combined with a quetiapine switch for those with psychotic symptoms was associated with reduced drug craving. Definitive trials of typical antipsychotic discontinuation in dual-diagnosis patients are warranted.

Original languageEnglish (US)
Pages (from-to)384-388
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume23
Issue number4
DOIs
StatePublished - Aug 2003

Fingerprint

Amphetamine
Cocaine
Antipsychotic Agents
Psychiatry
Pharmaceutical Preparations
Dual (Psychiatry) Diagnosis
Self Administration
Psychotic Disorders
Substance-Related Disorders
Outpatients

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Cocaine and amphetamine use in patients with psychiatric : Illness a randomized trial of typical antipsychotic continuation or discontinuation. / Brown, E. Sherwood; Nejtek, Vicki A.; Perantie, Dana C.; Thomas, Nancy Rajan; Rush, A. John.

In: Journal of Clinical Psychopharmacology, Vol. 23, No. 4, 08.2003, p. 384-388.

Research output: Contribution to journalArticle

@article{1135494224ec440189307333c49e727a,
title = "Cocaine and amphetamine use in patients with psychiatric: Illness a randomized trial of typical antipsychotic continuation or discontinuation",
abstract = "Animal studies indicate that typical antipsychotics (neuroleptics) increase cocaine and amphetamine self-administration. Patients with psychiatric illnesses have high rates of substance abuse and frequently receive chronic typical antipsychotic therapy. This open, pilot study examined the effect of typical antipsychotic discontinuation on cocaine and amphetamine use in patients with psychiatric illnesses. Twenty-four evaluable outpatients were randomized to continue (n = 12) or discontinue (n = 12) chronic typical antipsychotic therapy. The atypical antipsychotic quetiapine was instituted, when necessary, for psychosis in the discontinuation group (n = 8). Participants were assessed weekly over 12 weeks with measures of psychiatric symptoms, drug use, and drug craving. Those discontinuing typical antipsychotics (n = 12) had significant reductions in drug craving compared with those continuing typical antipsychotics. No significant between-group differences in drug use were found. Typical antipsychotic discontinuation combined with a quetiapine switch for those with psychotic symptoms was associated with reduced drug craving. Definitive trials of typical antipsychotic discontinuation in dual-diagnosis patients are warranted.",
author = "Brown, {E. Sherwood} and Nejtek, {Vicki A.} and Perantie, {Dana C.} and Thomas, {Nancy Rajan} and Rush, {A. John}",
year = "2003",
month = "8",
doi = "10.1097/01.jcp.0000085412.08426.08",
language = "English (US)",
volume = "23",
pages = "384--388",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cocaine and amphetamine use in patients with psychiatric

T2 - Illness a randomized trial of typical antipsychotic continuation or discontinuation

AU - Brown, E. Sherwood

AU - Nejtek, Vicki A.

AU - Perantie, Dana C.

AU - Thomas, Nancy Rajan

AU - Rush, A. John

PY - 2003/8

Y1 - 2003/8

N2 - Animal studies indicate that typical antipsychotics (neuroleptics) increase cocaine and amphetamine self-administration. Patients with psychiatric illnesses have high rates of substance abuse and frequently receive chronic typical antipsychotic therapy. This open, pilot study examined the effect of typical antipsychotic discontinuation on cocaine and amphetamine use in patients with psychiatric illnesses. Twenty-four evaluable outpatients were randomized to continue (n = 12) or discontinue (n = 12) chronic typical antipsychotic therapy. The atypical antipsychotic quetiapine was instituted, when necessary, for psychosis in the discontinuation group (n = 8). Participants were assessed weekly over 12 weeks with measures of psychiatric symptoms, drug use, and drug craving. Those discontinuing typical antipsychotics (n = 12) had significant reductions in drug craving compared with those continuing typical antipsychotics. No significant between-group differences in drug use were found. Typical antipsychotic discontinuation combined with a quetiapine switch for those with psychotic symptoms was associated with reduced drug craving. Definitive trials of typical antipsychotic discontinuation in dual-diagnosis patients are warranted.

AB - Animal studies indicate that typical antipsychotics (neuroleptics) increase cocaine and amphetamine self-administration. Patients with psychiatric illnesses have high rates of substance abuse and frequently receive chronic typical antipsychotic therapy. This open, pilot study examined the effect of typical antipsychotic discontinuation on cocaine and amphetamine use in patients with psychiatric illnesses. Twenty-four evaluable outpatients were randomized to continue (n = 12) or discontinue (n = 12) chronic typical antipsychotic therapy. The atypical antipsychotic quetiapine was instituted, when necessary, for psychosis in the discontinuation group (n = 8). Participants were assessed weekly over 12 weeks with measures of psychiatric symptoms, drug use, and drug craving. Those discontinuing typical antipsychotics (n = 12) had significant reductions in drug craving compared with those continuing typical antipsychotics. No significant between-group differences in drug use were found. Typical antipsychotic discontinuation combined with a quetiapine switch for those with psychotic symptoms was associated with reduced drug craving. Definitive trials of typical antipsychotic discontinuation in dual-diagnosis patients are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0042133408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042133408&partnerID=8YFLogxK

U2 - 10.1097/01.jcp.0000085412.08426.08

DO - 10.1097/01.jcp.0000085412.08426.08

M3 - Article

C2 - 12920415

AN - SCOPUS:0042133408

VL - 23

SP - 384

EP - 388

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 4

ER -